Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer

摘要: Introduction The role of trimodality therapy for locally advanced non-small cell lung cancer (NSCLC) continues to be defined. We hypothesized that imaging parameters on pre- and postradiation positron emission tomography (PET)-computed (CT) are prognostic outcome after preoperative chemoradiotherapy (CRT)/resection/consolidation chemotherapy could help risk-stratify patients in clinical trials. Methods enrolled 13 a prospective trial resectable NSCLC. PET-CT was acquired radiation planning 45 Gy. Gross tumor volume (GTV) standardized uptake value were measured at post-CRT time points correlated with nodal pathologic complete response, loco-regional and/or distant progression, overall survival. In addition, we evaluated the performance automatic deformable image registration (ADIR) software volumetric response assessment. Results All responded average total GTV reductions Gy 43% (range: 27–64%). Pre- GTVs highly ( R 2 = 0.9), their respective median values divided into same two groups. ADIR measurements agreed closely manually segmented GTVs. Patients ≥ (137 ml pre-CRT 67 post-CRT) had 3-year progression-free survival (PFS) 14% versus 75% less than median, significant difference p 0.049). PET-standardized did not correlate significantly PFS, or Conclusions Preoperative CRT carboplatin/docetaxel/45 resulted excellent rates. this exploratory analysis, predicted PFS therapy, consistent our earlier studies broader cohort seems robust enough assessment